Regulation of HIF-1 by oxygen: The role of prolyl hydroxylase and the VHL tumor suppressor

Oxygen Sensing: Responses and Adaption to Hypoxia

Volumn , Issue , 2003, Pages 47-64

  Maxwell, Patrick H ^a   Ratcliffe, Peter J ^b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 11144298441     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (95)

1. Jelkmann W. Erythropoietin: Structure, control of production, and function. Physiol Rev 1992; 72:449-489.
2. Lahiri S. Historical perspectives of cellular oxygen sensing and responses to hypoxia. J Appl Physiol 2000; 88:1467-1473.
3. Maxwell PH, Osmond MK, Pugh CW, Heryet A, Nicholls LG, Tan CC, Doe BG, Ferguson DJP, Johnson MH, Ratcliffe PJ. Identification of the renal erythropoietin-producing cells using transgenic mice. Kidney Int 1993; 44:1149-1162.
4. Bachmann S, Le Hir M, Eckardt K-U. Co-localization of erythropoietin messenger RNA and ecto-5′-nucleotidase immunoreactivity in peritubular cells of rat renal cortex indicates that fibroblasts produce erythropoietin. J Histochem Cytochem 1993; 41: 335-341.
5. Wang GL, Semenza GL. Characterization of hypoxia-inducible factor 1 and regulation of DNA binding activity by hypoxia. J Biol Chem 1993; 268:21513-21518.
6. 2 tension. Proc Natl Acad Sci USA 1995; 92:5510-5514.
7. Maxwell PH, Pugh CW, Ratcliffe PJ. Inducible operation of the erythropoietin 3′ enhancer in multiple cell lines: evidence for a widespread oxygen sensing mechanism. Proc Natl Acad Sci USA 1993; 90:2423-2427.
8. Semenza GL. HIF-1: mediator of physiological and pathophysiological responses to hypoxia. J Appl Physiol 2000; 88:1474-1480.
9. Jiang H, Guo R, Powell-Coffman JA. The Caernorhabditis elegans hif-1 gene encodes a bHLHPAS protein that is required for adpatation to hypoxia. Proc Natl Acad Sci USA 2001; 98:7916-7921.
10. Epstein ACR, Gleadle JM, McNeill LA, Hewitson KS, O’Rourke J, Mole DR, Mukherji M, Metzen E, Wilson MI, Dhanda A, Tian Y-M, Masson N, Hamilton DL, Jaakkola P, Barstead R, Hodgkin J, Maxwell PH, Pugh CW, Schofield CJ, Ratcliffe PJ. C. elegans EGL-9 and mammalian homologues define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 2001; 107:43-45.
11. Nagao M, Ebert BL, Ratcliffe PJ, Pugh CW. Drosophila melanogaster SL2 cells contain a hypoxically inducible DNA binding complex which recognises mammalian HIF-1 binding sites. FEBS Lett 1996; 387:161-166.
12. Bacon NC, Wappner P, O’Rourke JF, Bartlett SM, Shilo B, Pugh CW, Ratcliffe PJ. Regulation of the Drosophila basic helix-loop-helix PAS protein Sima by hypoxia: functional evidence for homology with mammalian HIF-1 alpha. Biochem Biophy Res Commun 1998; 249:811-816.
13. Salceda S, Caro J. Hypoxia-inducible factor lα (HIF-1α) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. J Biol Chem 1997; 272:22642-22647.
14. Pugh CW, O’Rourke JF, Nagao M, Gleadle JM, Ratcliffe PJ. Activation of hypoxia inducible factor-1. definition of regulatory domains within the a subunit. J Biol Chem 1997; 272:11205-11214.
15. Huang LE, Gu J, Schau M, Bunn HF. Regulation of hypoxia-inducible factor lα is mediated by an oxygen-dependent domain via the ubiquitin-proteasome pathway. Proc Natl Acad Sci USA 1998; 95:7987-7992.
16. Wiesener MS, Turley H, Allen WE, William C, Eckardt K-U, Talks KL, Wood SM, Gatter KC, Harris AL, Pugh CW, Ratcliffe PJ, Maxwell PH. Induction of endothelial PAS domain protein-1, by hypoxia: characterization and comparison with hypoxiainducible factor-1α. Blood 1998; 92:2260-2268.
17. Kallio PJ, Okamoto K, O’Brien S, Carrero P, Makino Y, Tanaka H, Poellinger L. Signal transduction in hypoxic cells: inducible nuclear translocation and recruitment of the CBP/p300 coactivator by the hypoxia-inducible factor-1α. EMBO J 1998; 17:6573-6586.
18. Ema M, Hirota K, Mimura J, Abe H, Yodoi J, Sogawa K, Poellinger L, Fujii-Kuriyama Y. Molecular mechanisms of transcription activation by HLF and HIF 1 alpha in response to hypoxia: their stabilization and redox signal-induced interaction with CBP/p300. EMBO J 1999; 18:1905-1914.
19. Bhattacharya S, Michels CL, Leung M-K, Arany ZP, Kung AL, Livingston DM. Functional role of p35srj, a novel p300/CBP, binding protein, during transactivation by HIF-1. Genes Dev 1999; 13:64-75.
20. Goldwasser E, Jacobson LO, Fried W, Plazk LF. Studies on erythropoiesis V: The effect of cobalt on the production of erythropoietin. Blood 1958; 13:55-60.
21. Goldberg MA, Dunning SP, Bunn HE Regulation of the erythropoietin gene: evidence that the oxygen sensor is a heme protein. Science 1988; 242:1412-1415.
22. Wang GL, Semenza GL. Desferrioxamine induces erythropoietin gene expression and hypoxiainducible factor 1 DNA-binding activity: implications for models of hypoxia signal transduction. Blood 1993; 82:3610-3615.
23. Ho VT, Bunn HF. Effects of transition metals on the expression of the erythropoietin gene:further evidence that the oxygen sensor is a heme protein. Biochem Biophy Res Commun 1996; 223:175-180.
24. Gilles-Gonzalez MA, Gonzalez G, Perutz MF. Heme-based sensors, exemplified by the kinas FixL, are a new class of heme protein with distinctive ligand binding and autoxidation. Biochemistry 1994; 33:8067-8073.
25. Hidalgo E, Ding H, Demple B. Redox signal transduction: mutations shifting [2Fe-2S] centers of the SoxR sensor-regulator to the oxidized form. Cell 1997; 88:121-129.
26. Fandrey J, Frede S, Jelkmann W. Role of hydrogen peroxide in hypoxia-induced erythropoietin production. Biochem J 1994; 303:507-510.
27. Acker H. Mechanisms and meaning of cellular oxygen sensing in the organism. Respir Physiol 1994; 95:1-10.
28. Zhu H, Qiu H, Yoon H-W, Huang S, Bunn H. Identification of a cytochrome b-type NAD(P)H oxidoreductase ubiquitously expressed in human cells. Proc Natl Acad Sci USA 1999; 96:14742-14747.
29. Chandel NS, McClintock DS, Feliciano CE, Wood TM, Melendez JA, Rodriguez AM, Schumacker PT. Reactive oxygen species generated at mitochondrial complex III stabilize hypoxia-inducible factor-1. alpha during hypoxia: a mechanism of oxygen sensing. J Biol Chem 2000:1-37.
30. Chandel NS, Maltepe E, Goldwasser E, Mathieu CE, Simon MC, Schumacker PT. Mitochondrial reactive oxygen species trigger hypoxia-induced transcription. Proc Natl Acad Sci USA 1998; 95:11715-11720.
31. Storz G, Imlay J. Oxidative stress. Curr Opin Microbiol 1999; 2:188-194.
32. Maxwell PH, Wiesener MS, Chang G-W, Clifford SC, Vaux EC, Cockman ME, Wykoff CC, Pugh CW, Maher ER, Ratcliffe PJ. The tumour suppressor protein VHL targets hypoxiainducible factors for oxygen-dependent proteolysis. Nature 1999; 399:271-275.
33. Latif F, Tory K, Gnarra J, Yao M, Duh F-M, Orcutt ML, Stackhouse T, Kuzmin I, Modi W, Geil L, Schmidt L, Zhou F, Li H, Wei MH, Chen F, Glenn G, Choyke P, Walther MM, Weng Y, Duan D-SR, Dean M, Glavac D, Richards FM, Crossey PA, Ferguson-Smith MA, Le Paslier D, Chumakov I, Cohen D, Chinault AC, Maher ER, Linehan WM, Zbar B, Lerman MI. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 1993; 260:1317-1320.
34. Gnarra JR, Tory K, Weng Y, Schmidt L, Wei MH, Li H, Latif F, Liu S, Chen F, Duh F-M, Lubensky I, Duan DR, Florence C, Pozzatti R, Walther MM, Bander NH, Grossman HB, Brauch H, Pomer S, Brooks JD, Isaacs WB, Lerman MI, Zbar B, Linehan WM. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nature Genet 1994; 7:85-90.
35. Kanno H, Kondo K, Ito S, Yamamoto I, Fujii S, Torigoe S, Sakai N, Hosaka M, Shuin T, Yao M. Somatic mutations of the Von Hippel-Lindau tumor suppressor gene in sporadic central nervous system hemangioblastomas. Cancer Res 1994; 54:4845-4847.
36. 19 is a biologically active product of the von Hippel-Lindau gene arising from internal translation initiation. Proc Natl Acad Sci USA 1998; 95:11661-11666.
37. Schoenfeld A, Davidowitz EJ, Burk RD. A second major native von Hippel-Lindau gene product, initiated from an internal translation start site, functions as a tumor suppressor. Proc Natl Acad Sci USA 1998; 95:8817-8822.
38. Kamura T, Sato S, Iwai K, Czyzyk-Krzeska M, Conaway RC, Conaway JW Activation of HIF1α ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex. Proc Natl Acad Sci USA 2000; 97:10430-10435.
39. Cockman ME, Masson N, Mole DR, Jaakkola P, Chang GW, Clifford SC, Maher ER, Pugh CW, Ratcliffe PJ, Maxwell PH. Hypoxia inducible factor-α binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J Biol Chem 2000; 275:25733-25741.
40. Ohh M, Park CW, Ivan M, Hoffman MA, Kim TY, Huang LE, Pavletich N, Chau V, Kaelin WG. Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nat Cell Biol 2000; 2:423-427.
41. Duan DR, Pause A, Burgess WH, Aso T, Chen DYT, Garrett KP, Conaway RC, Conaway JW, Linehan WM, Klausner RD. Inhibition of transcription elongation by the VHL tumor suppressor protein. Science 1995; 269:1402-1406.
42. Kibel A, Iliopoulos O, DeCaprio JA, Kaelin WG, Jr. Binding of the von Hippel-Lindau tumor suppressor protein to elongin B and C. Science 1995; 269:1444-1446.
43. Pause A, Lee S, Worrell RA, Chen DYT, Burgess WH, Linehan WM, Klausner RD. The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins. Proc Nat Acad Sci USA 1997; 94:2156-2161.
44. Lonergan KM, Iliopoulos O, Ohh M, Kamura T, Conaway RC, Weliky Conaway J, Kaelin WG, Jr. Regulation of hypoxia-inducible mRNAs by the von Hippel-Lindau tumor suppressor protein requires binding to complexes containing elongins B/C and (Cul2), Mol Cell Biol 1998; 18:732-741.
45. Kamura T, Koepp DM, Conrad MN, Skowyra D, Moreland RJ, Iliopoulos O, Lane WS, Kaelin WG, Jr., Elledge SJ, Conaway RC, Harper JW, Conaway JW. Rbx1, a component of the VHL tumor suppressor complex and SCF ubiquitin ligase. Science 1999; 284:657-661.
46. Stebbins CE, Kaelin WG, Jr., Pavletich NP. Structure of the VHL-ElonginC-ElonginB complex: implications for VHL tumor suppressor function. Science 1999; 284:455-461.
47. Haase VH, Glickman, JN, Socolovsky M, Jaenisch, R. Vascular tumors in livers with targeted inactivation of the von Hippel-Lindau tumor suppressor. Proc Nat Acad Sci USA 2001; 98:1583-1588.
48. Vaux EC, Wood SM, Cockman ME, Nicholls LG, Yeates KM, Pugh CW, Maxwell PH, Ratcliffe PJ. Selection of mutant CHO cells with constitutive activation of the HIF system and inactivation of the von Hippel-Lindau tumor suppressor. J Biol Chem 2001; 276:44323-44330.
49. 2-regulated prolyl hydroxylation. Science 2001; 292:468-472.
50. 2 sensing. Science 2001; 292:464-468.
51. Kornitzer D, Ciechanover A. Modes of regulation of ubiquitin-mediated protein degradation. J Cell Physiol 2000; 182:1-11.
52. Masson N, Willam C, Maxwell PH, Pugh CW, Ratcliffe PJ. Independent function of two destruction domains in hypoxia-inducible factor-α chains activated by prolyl hydroxylation. EMBO J 2001; 20:5197-5206.
53. Schofield CJ, Zhang Z. Structural and mechanistic studies on 2-oxoglutarate-dependent oxygenases and related enzymes. Curr Opin Struct Biol 1999; 9:722-731.
54. Hegg EL, Que L. The 2-His-l-carboxylate facial triad-an emerging structural motif in mononuclear non-heme iron (II) enzymes. Eur J Biochem 1997; 250:625-629.
55. Kivirikko KI, Myllyharju J. Prolyl 4-hydroxylases and their protein disulfide isomerase subunit. Matrix Biol 1998; 16:357-368.
56. Bruick RK, McKnight SL. A conserved family of prolyl-4-hydroxylases that modify HIF. Science 2001; 11:11.
57. Trent C, Tsung N, Horvitz HR. Egg-laying defective mutants of the nematode Caenorhabditis elegans. Genetics 1983; 104:619-647.
58. Gallagher LA, Manoil C. Pseudomonas aeruginosa PAO1 kills Caenorhabditis elegans by cyanide poisoning. J Bacteriol 2001; 183:6207-6214.
59. Berra E, Richard DE, Gothic E, Pouyssegur J. HIF-1-dependent transcriptional activity is required for oxygen-mediated HIF-1α degradation. FEBS Lett 2001; 491:85-90.
60. Wax SD, Rosenfield CL, Taubman MB. Identification of a novel growth factor-responsive gene in vascular smooth muscle cells. J Biol Chem 1994; 269:13041-13047.
61. Madden SL, Galella EA, Riley D, Bertelsen AH, Beaudry GA. Induction of cell growth regulatory genes by p53. Cancer Res 1996; 56:5384-5390.
62. Lipscomb EA, Sarmiere PD, Crowder RJ, Freeman RS. Expression of the SM-20 gene promotes death in nerve growth factor-dependent sympathetic neurons. J Neurochemi 1999; 73:429-432.
63. Lipscomb EA, Sarmiere PD, Freeman RS. SM-20 is a novel mitochondrial protein that causes caspase-dependent cell death in nerve growth factor-dependent neurons. J Biol Chem 2001; 276:5085-5092.
64. Plisov SY, Ivanov SV, Yoshino K, Dove LF, Plisova TM, Higinbotham KG, Karavanova I, Lerman M, Perantoni AO. Mesenchymal-epithelial transition in the developing metanephric kidney: gene expression study by differential display. Genesis 2000; 27:22-31.
65. Lee S, Chen DYT, Humphrey JS, Gnarra JR, Linehan WM, Klausner RD. Nuclear/cytoplasmic localization of the von Hippel-Lindau tumor supressor gene product is determined by cell density. Proc Nat Acad Sci USA 1996; 93:1770-1775.
66. Los M, Jansen GH, Kaelin WG, Lips CJM, Blijham GH, Voest EE. Expression pattern of the von Hippel-Lindau protein in human tissues. Lab Invest 1996; 75:231-238.
67. Corless CL, Kibel AS, Iliopoulos O, Kaelin WG, Jr. Immunostaining of the von Hippel-Lindau gene product in normal and neoplastic human tissues. Hum Pathol 1997; 28:459-464.
68. Lee S, Neumann M, Stearman R, Stauber R, Pause A, Pavlakis GN, Klausner RD. Transcription-dependent nuclear-cytoplasmic trafficking is required for the function of the von Hippel-Lindau tumor suppressor protein. Mol Cell Biol 1999; 19:1486-1497.
69. Groulx I, Bonicalzi ME, Lee S. Ran-mediated nuclear export of the von Hippel-Lindau tumor suppressor protein occurs independently of its assembly with cullin-2. J Biol Chem 2000; 275:8991-9000.
70. Ye Y, Vasavada S, Kuzmin I, Stackhouse T, Zbar B, Williams BRG. Subcellular localization of the von Hippel-Lindau disease gene product is cell cycle-dependent. Int J Cancer 1998; 78:62-69.
71. Tanimoto K, Makino Y, Pereira T, Poellinger L. Mechanism of regulation of the hypoxiainducible factor-1α by the von Hippel-Lindau tumor suppressor protein. EMBO J 2000; 19:4298-4309.
72. Genbacev O, Krtolica A, Kaelin W, Fisher SJ. Human cytotrophoblast expression of the von Hippel-Lindau protein is downregulated during uterine invasion in situ and upregulated by hypoxia in vitro. Dev Biol 2001; 233:526-536.
73. Mahon PC, Hirota K, Semenza GL. FIH-1: a novel protein that interacts with HIF-1 alpha and VHL to mediate repression of HIF-1 transcriptional activity. Genes Dev 2001; 15:2675-2686.
74. Iliopoulos O, Levy AP, Jiang C, Kaelin WG Jr, Goldberg MA. Negative regulation of hypoxiainducible genes by the von Hippel-Lindau protein. Proc Nat Acad Sci USA 1996; 93:10595-10599.
75. Pioli PA, Rigby WFC. The von Hippel-Lindau protein interacts with hnRNP A2 and regulates its expression. J Biol Chem 2001; 276:40346-40352.
76. Ohh M, Yauch RL, Lonergan KM, Whaley JM, Stemmer-Rachamimov AO, Louis DN, Gavin BJ, Kley N, Kaelin WG, Jr, Iliopoulos O. The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix. Mol Cell 1998; 1:959-968.
77. Mukhopadhyay D, Knebelmann B, Cohen HT, Ananth S, Sukhatme VP. The von Hippel-Lindau tumor suppressor gene product interacts with Sp1 to repress vascular endothelial growth factor promoter activity. Mol Cell Biol 1997; 17:5629-5639.
78. Tsuchiya H, Iseda T, Hino O. Identification of a novel protein (VBP-1) binding to the von Hippel-Lindau (VHL) tumor suppressor gene product. Cancer Res 1996; 56:2881-2885.
79. Li Z, Na X, Wang D, Schoen SR, Messing EM, Wu G. Ubiquitination of a novel deubiquitinating enzyme requires direct binding to von Hippel-Lindau tumor suppressor protein. J Biol Chem 2001; 5:5.
80. Semenza GL. Hypoxia, clonal selection, and the role of HIF-1 in tumor progression. Crit Rev Biochem Mol Biol 2000; 35:71-103.
81. Maxwell PH, Pugh CW, Ratcliffe PJ. Activation of the HIF pathway in cancer. Curr Opin Genet Dev 2001; 11:293-299.
82. Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D, Buechler P, Isaacs WB, Semenza GL, Simons JW. Overexpression of hypoxia-inducible factor lα in common human cancers and their metastases. Cancer Res 1999; 59:5830-5835.
83. Talks K, Turley H, Gatter KC, Maxwell PH, Pugh CW, Ratcliffe PJ, Harris AL. The expression and distribution of the hypoxia-inducible factors HIF-1 alpha and (HIF-2alpha) in normal human tissues, cancers, and tumor-associated macrophages. Am J Pathol 2000; 157:411-421.
84. Maxwell PH, Dachs GU, Gleadle JM, Nicholls LG, Harris AL, Stratford IJ, Hankinson O, Pugh CW, Ratcliffe PJ. Hypoxia inducible factor-1. modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc Nat Acad Sci USA 1997; 94:8104-8109.
85. Ryan HE, Poloni M, McNulty W, Elson D, Gassmann M, Arbeit JM, Johnson RS. Hypoxiainducible factor-1α is a positive factor in solid tumor growth. Cancer Res 2000; 60:4010-4015.
86. Ryan HE, Lo J, Johnson RS. HIF-1α is required for solid tumor formation and embryonic vascularization. EMBO J 1998; 17:3005-3015.
87. Carmeliet P, Dor Y, Herbert J-M, Fukumura D, Brusselmans K, Dewerchin M, Neeman M, Bono F, Abramovitch R, Maxwell PH, Koch CJ, Ratcliffe PJ, Moons L, Jain RK, Collen D, Keshert E. Role of HIF-1 alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 1998; 394:485-490.
88. Brusselmans K, Bono F, Maxwell P, Dor Y, Dewerchin M, Collen D, Herbert JM, Carmeliet P. Hypoxia-inducible factor-2alpha (HIF-2alpha) is involved in the apoptotic response to hypoglycemia but not to hypoxia. J Biol Chem 2001; 276:39192-39196.
89. Bruick RK. Expression of the gene encoding the proapoptotic Nip3 protein is induced by hypoxia. Proc Nat Acad Sci USA 2000; 97:9082-9087.
90. Sowter HM, Ratcliffe PJ, Watson P, Greenberg AH, Harris AL. HIF-1-dependent regulation of hypoxic induction of the cell death factors BNIP3 and NIX in human tumors. Cancer Res 2001; 61:6669-6673.
91. Hoffman MA, Ohh M, Yang H, Klco JM, Ivan M, Kaelin WGJ. von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF. Hum Mol Genet 2001; 10:1019-1027.
92. Clifford SC, Cockman ME, Smallwood AC, Mole DR, Woodward ER, Maxwell PH, Ratcliffe PJ, Maher ER. Contrasting effects on HIF-1α regulation by disease-causing pVHL, mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease. Hum Mol Genet 2001; 10:1029-1038.
93. Elson DA, Thurston G, Huang LE, Ginzinger DG, McDonald DM, Johnson RS, Arbeit JM. Induction of hypervascularity without leakage or inflammation in transgenic mice overexpressing hypoxia-inducible factor-1, alpha. Genes Dev 2001; 15:2520-2532.
94. Dupuy D, Aubert I, Duperat VG, Petit J, Taine L, Stef M, Bloch B, Arveiler B. Mapping, characterization, and expression analysis of the SM-20 human homologue, cl orf12, and identification of a novel related gene, SCAND2. Genomics 2000; 69:348-354.
95. Taylor MS. Characterization and comparative analysis of the EGLN gene family. Gene 2001; 275:125-132.